[drug name]

　　General name: Escitalopram Oxalate Tablets

　　Product Name: Escitalopram Oxalate Tablets 10mg*7 tablets

　　Pinyin full code: BaiLuoTe CaoSuanAiSiXiTaiPuLanPian 10mg*7Pian

　　[main ingredients]

　　This product is mainly composed of oxalic acid Ai Sciplan.

　　[character]

　　This product is a film coated tablet, which is white after removing the film coating.

　　Indications / indications

　　Treat depression. Treatment of panic disorder with or without agoraphobia.

　　[specification type]

　　10mg*7 film (100)

　　[usage and dosage]

　　Usage: orally, can be served with food. Dosage: 1 times a day. The usual dose is 10mg per day, and the maximum daily dose can be increased to 20mg according to the patient's individual reaction. Antidepressant effects can usually be obtained in 2-4 weeks. After symptomatic remission, continuous treatment should be continued for at least 6 months to consolidate the curative effect. Older patients (> 65 years old) are recommended to start treatment with half of the above routine initial dose, and the maximum dose should be reduced accordingly. Children and adolescents (< 18 years old) have not yet conducted efficacy and safety studies in this population and are not recommended for use in this population. In patients with mild or moderate renal impairment (CLCR < 30ml/min), dosage adjustment is not necessary. Patients with severe renal impairment should be cautious. For patients with reduced liver function, the initial dose should be 5mg per day for 2 weeks. According to the patient's individual response, the dose can be increased to 10mg per day. CYP2C19 slow metabolizer for patients with known CYP2C19 slow metabolizer, the initial dose of 5 mg per day, continuous treatment for 2 weeks, according to the patient's individual response, can increase the dose to 10 mg per day. When discontinuation symptoms require discontinuation of this product, dosage should be gradually reduced within 1 to 2 weeks to avoid discontinuation symptoms. The safety of more than 20mg a day has not been proven.

　　[adverse reactions]

　　Foreign literatures reported that adverse reactions mostly occurred in the first to second weeks of treatment, and the severity and incidence of adverse reactions would be reduced after continuous treatment. After a sudden withdrawal of SSRI drugs for a long time, some patients may have withdrawal symptoms. Although withdrawal symptoms may occur after withdrawal of SSRI drugs, there is no pre-clinical and clinical evidence that SSRI drugs can lead to dependence. The withdrawal reaction of citalopram has not been systematically evaluated. The withdrawal reaction of citalopram has been observed, which is characterized by dizziness, headache and nausea, most of which are mild and self-limited. In the double-blind placebo-controlled study conducted abroad, the following adverse reactions were more common than those of placebo, and the incidence was not corrected by placebo.

　　Xie and malnutrition are common (>1/100, <1/10);

　　Decreased appetite is commonly seen in psychotic disorders (>1/100, <1/10).

　　Decreased sexual desire and sexual pleasure disorder (female) are common in nervous system disorders (>1/100, <1/10).

　　Insomnia, drowsiness and dizziness are rare (>1/1000, <1/100).

　　Abnormal taste, sleep disorders, respiratory system, chest and diaphragmatic regions are common (>1/100, <1/10).

　　Nasosinusitis and yawn gastrointestinal system abnormalities are very common (>1/10).

　　Nausea is common (>1/100, <1/10).

　　Diarrhea and constipation were common in skin and subcutaneous tissue (>1/100, <1/10).

　　Hyperhidrosis and breast abnormalities are common (>1/100, <1/10).

　　Ejaculation disorder, impotence, systemic symptoms and local drug abnormality were common (>1/100, <1/10).

　　Fatigue and fever

　　The following are the adverse reactions of SSRI drugs: metabolic and nutritional disorders: hyponatremia, abnormal secretion of antidiuretic hormone; psychiatric disorders: hallucination, mania, confusion of consciousness, agitation, anxiety, personality changes, panic attacks, neuroticism; neurological disorders: seizures, tremors, motor disorders, serotonin synthesis Symptoms; Eye: Visual abnormalities; Cardiovascular system: Postural hypotension; Gastrointestinal system: nausea, vomiting, dry mouth, diarrhea, anorexia; Liver and gallbladder system: abnormal liver function; Skin and subcutaneous tissue: rash, ecchymosis, pruritus, vascularized edema and sweating; Musculoskeletal system: arthralgia and myalgia; Kidney; And urinary system: urinary retention; reproductive system: galactorrhea, sexual function, including: impotence, ejaculation disorders, loss of sexual pleasure; systemic symptoms: insomnia, dizziness, fatigue, sleepiness and allergic reactions.

　　[taboo]

　　1. it is forbidden to use the active ingredient or any excipient allergy.

　　2. Combination with non-selective and irreversible monoamine oxidase inhibitors (MAOL) is prohibited (see [warning] and [drug interaction].

　　3. prohibition of combination with linezolid, see drug interactions.

　　4. prohibition of combination with the drug for drug use. See drug interactions.

　　5. it is forbidden to use this product in patients with prolonged QT interval or congenital QT syndrome.

　　[note]

　　Antidepressants are not suitable for children and adolescents under the age of 18. In the clinical trials of children and adolescents under 18 years of age, it was found that the frequency of suicide-related behaviors (suicide attempts and suicide ideas) and hostility (aggression, confrontation and irritability) in this group was higher than that in the placebo group. Even for clinical trials, the patient's suicide performance is still closely monitored. The following special warnings and caution apply to all kinds of SSRI drugs. Contradictory Anxiety Some panic disorder patients may aggravate anxiety symptoms at the beginning of antidepressant treatment. This contradictory reaction usually develops within two weeks after the beginning of treatment.